Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

841
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
841
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

778
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
778
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

1.6K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
1.6K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.7K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.7K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

890
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
890

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From guideline to precision: echocardiography in the management of cardiogenic shock.

Current opinion in critical care·2026
Same author

Incidence and Outcomes of Refractory Septic Shock per Consensus Clinical Criteria: A Multicohort Retrospective Study.

Critical care medicine·2026
Same author

Implementation and Assessment of a Novel Interprofessional Educational Initiative in the Medical Intensive Care Unit: A Mixed-Methods Evaluation.

ATS scholar·2026
Same author

The Weight of the Situation: The Case for Standardizing Vasopressor Dosing Units.

Critical care medicine·2026
Same author

Fighting ageism: Preserving patient agency in critical care.

Cleveland Clinic journal of medicine·2026
Same author

Defining and Measuring Patient-Ventilator Interactions: 10 Fundamental Maxims.

Respiratory care·2026

Related Experiment Video

Updated: Jul 18, 2025

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

10.2K

Peripheral Administration of Norepinephrine: A Prospective Observational Study.

Jason R Yerke1, Eduardo Mireles-Cabodevila2, Alyssa Y Chen1

  • 1Department of Pharmacy, Cleveland Clinic, Cleveland, OH.

Chest
|August 23, 2023
PubMed
Summary
This summary is machine-generated.

Peripheral administration of norepinephrine safely reduces central venous catheter (CVC) use, avoiding 1 CVC day per patient. Over half of patients receiving norepinephrine peripherally avoided CVC insertion altogether.

Keywords:
catheterhypotensioninfusionsnorepinephrineparenteralshockvasoconstrictor agents

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.6K
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

9.9K

Related Experiment Videos

Last Updated: Jul 18, 2025

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

10.2K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.6K
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

9.9K

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Vascular Access

Background:

  • Norepinephrine traditionally administered via central venous catheter (CVC) due to extravasation concerns.
  • Emerging evidence suggests peripheral administration of norepinephrine may be safe.
  • Peripheral IV catheters (PIVCs) offer potential benefits over CVCs if safety is established.

Purpose of the Study:

  • To evaluate the safety and efficacy of a protocol for peripheral norepinephrine administration.
  • To determine if peripheral norepinephrine use can reduce central venous catheter (CVC) days and frequency of placement.
  • To assess the incidence of extravasation events and associated tissue injury.

Main Methods:

  • Prospective observational cohort study in a medical intensive care unit (ICU).
  • Implementation of a protocol for peripheral norepinephrine administration based on prespecified criteria.
  • Inclusion of adult patients receiving norepinephrine via PIVC between February 2019 and June 2021.

Main Results:

  • Median of 1 central venous catheter (CVC) day avoided per patient.
  • 51.6% of patients receiving norepinephrine peripherally as initial exposure never required CVC insertion.
  • Extravasation occurred in 35 patients (75.8 events/1,000 days of PIVC infusion), with most causing minimal injury; no surgical intervention was needed.

Conclusions:

  • Implementing a protocol for peripheral norepinephrine administration can safely avoid approximately 1 CVC day per patient.
  • Over half of patients can avoid CVC insertion with peripheral norepinephrine administration.
  • Further randomized, multicenter trials are warranted to confirm net benefits compared to CVC administration.